726 results about "Treatment targets" patented technology

A neurophysiological magnetic stimulation (NMS) method includes obtaining motor thresholds over one or both motor strips adhered to the patient's head or the equivalent anatomic region for treatment of non-brain, nervous system disorders. The method further includes applying magnetic stimulation coils to a therapeutic target region of the patient's brain, brainstem, spinal cord, or peripheral nervous system and applying NMS in increasing amplitudes as tolerated over the course of treatment.

An ablation catheter for treating electrical rhythm disorders includes an array of sensor electrodes to detect electrical signals to determine a location of a target region for treatment. If the catheter is not optimally positioned at the target region, a controller uses the detected signals to guide movement of the catheter towards the target region. Once proper positioning is ascertained, the controller activates ablation components within the catheter to deliver energy to modify tissue at the target region.

The invention relates to a system for adapting an orthodontic apparatus intended for a patient, said system comprising the following steps: -a) determining, at a parameterisation time, by a first dental healthcare professional and specifically for said patient, conditions for communicating updated information relating to the configuration of the patient's dentition; -b) acquiring, at an updated time subsequent to the parameterisation time, by means of an acquisition device and by the patient or an acquaintance of the patient, an extraoral depiction of at least one portion of the patient's dental arches, referred to as an “updated depiction”, said updated depiction consisting of a set of images and / or of a three-dimensional digital model; -c) analysing said updated depiction, so as to determine information regarding said dentition configuration at the updated time, or “updated information”, the updated information consisting of a set of information elements, each expressing a status for a relevant treatment aim in light of the updated depiction; -d) communicating the updated information to at least one second dental healthcare professional under the conditions determined in step a); -e) adapting said orthodontic apparatus on the basis of the updated information communicated in step d).

The invention provides a cerebral palsy child gastrocnemius spasm curative effect evaluation method and system. According to the system, electroencephalogram data, MR I images, ultrasonic elastography and gastrocnemius spasm curative effect grades are utilized to construct a cross-modal gastrocnemius spasm curative effect evaluation model; the constructed cross-modal gastrocnemius spasm curative effect evaluation model generates the current gastrocnemius spasm curative effect grade of the user according to the real-time electroencephalogram data collected by the server, the MR I images in the selected time period and the corresponding ultrasonic elastography; and according to the current gastrocnemius spasm curative effect grade of the user, flexible rehabilitation adjustment is performed on the user so as to realize a humanized treatment target. According to the invention, the doctor can monitor the rehabilitation training curative effect in real time, the intelligent curative effect evaluation effect is realized, and the life quality of the user is ensured.

The invention provides an individualized TMS target positioning method and system for spastic cerebral palsy children, and aims to realize TMS precise nerve regulation and control for different types of SCP children. According to the method, the structural features of the healthy child are obtained, and after image processing, accurate division of the SCP child brain region is achieved, the defects of a current brain injury child brain region spectrogram are overcome, and a basis is provided for seed point selection of different SCP symptoms; multi-modal image parameter features are further scanned, whole-brain voxel correlation analysis is performed based on seed points to construct functional connection diagrams, the crossed and overlapped functional connection diagrams are searched to serve as a liability focus network of different symptoms, a voxel set close to the scalp surface serves as a TMS target, and SCP child treatment targets of different clinical symptoms are accurately positioned. Based on a focus network mapping technology, functional connection characteristics related to different symptoms or symptom complexes are better positioned, a specific brain network is identified, and an accurate intervention target is provided for TMS treatment.

The invention discloses application of LECT2 as a diagnosis and treatment target of hepatic ischemia reperfusion injury. According to the present invention, the Print method operation patient sample is detected to discover that the expression of the LECT2 in the hepatic ischemia reperfusion injury is up-regulated; on the basis, a liver ischemia reperfusion injury model is constructed by knocking out a mouse through the LECT2 gene, and a result shows that the liver ischemia reperfusion injury of the mouse is obviously reduced by knocking out the LECT2 gene and transferring the LECT2-shRNA into the LECT2 gene, and the liver ischemia reperfusion injury of the mouse is aggravated by LECT2 recombinant protein; it is shown that inhibition of expression of LECT2 is beneficial to improvement or treatment of hepatic ischemia injury; furthermore, the invention further finds that liver injury can be relieved by inhibiting the combination of LECT2 and Tie1; the LECT2 / Tie1 signal channel can also be used as a target spot for treating the liver ischemia reperfusion injury.

The invention discloses a hospital static therapy-based static therapy informatization tracking method and system, and relates to the technical field of static therapy information tracking, and the method comprises the following steps: a medical worker sets an initial venous transfusion flow rate for a patient according to the illness state, weight, age and drug characteristics of the patient and a treatment target; during intravenous infusion of the patient, heart rate information of the patient is obtained in real time through monitoring equipment; the method comprises the following steps: preprocessing acquired original heart rate data, extracting key features, and performing anomaly analysis on the extracted heart rate features in a short-time monitoring window; by acquiring the heart rate information of the patient in real time and combining the machine learning model, the venous transfusion flow rate is dynamically adjusted, and personalized management is achieved. When the heart rate is abnormal, the system automatically reduces the flow rate, the heart burden is reduced, and the safety is improved; under the conventional heart rate, the flow speed is increased, and the infusion efficiency is improved. The intelligent adjusting mechanism not only improves the treatment effect, but also reduces the workload of medical staff and improves the nursing efficiency.

The invention relates to the technical field of medicines, in particular to a construction method and application of a photothermal conversion platform for treating osteoarthritis by regulating synovial macrophage polarization. According to the present invention, the M2 membrane-structured black phosphorus selenium carbon body (M2-BPSeC) photo-thermal nano-platform is innovatively provided, the triple functions of bionic targeting delivery, precise thermal control intervention and immune microenvironment remodeling are integrated, and the excellent synergistic treatment effect is represented in the in-vitro cell model and the OA animal model. The technology breaks through the technical bottleneck that traditional treatment is insufficient in targeting and single in intervention dimension, precise functional coupling of the physical thermal effect and immunoregulation is achieved for the first time, and a brand new strategy of targeting-temperature control-immunity integration is provided for osteoarthritis treatment. The efficient and controllable preparation process and the remarkable multi-dimensional treatment effect open up a new path for cartilage regeneration and immune balance regulation and control.

A substrate treatment apparatus includes a nozzle, a moving mechanism, a storage portion, and a control portion. The learned model is generated by learning, as learning data, learning target speed information indicating a moving speed of the nozzle and the amount of treatment acquired by executing a treatment on a substrate that is a learning target while causing the nozzle to move at a speed based on the learning target speed information. The control portion causes speed information at the time of treatment to be outputted from the learned model by inputting a target amount of an amount of treatment to the learned model. The control portion controls a moving mechanism such that the nozzle moves at a speed based on the speed information at the time of treatment when the treatment is executed on a substrate that is a treatment target.

A small animal imaging and radiotherapy (RT) irradiator device uses a circular array x-ray source to scan an anatomy of an animal, delivers conventional and ultra-high dose rate of radiation to the treatment target. The multipixel x-ray source includes a ring of focal spots capable of irradiating x-ray beams from around fifty beam angles. The x-ray beams are collimated with a collimator designed in treatment planning.

Method for evaluating a plurality of candidate delivery locations (130, a to c) for a delivery of a substance by a vascular catheter (200) for treatment of a target (120) within an organ (110) of a subject comprising: receiving a three-dimensional model obtained from a three-dimensional medical image of at least a part of the organ (110) of the subject, wherein the three-dimensional model includes arterial lumens, and determining from the three-dimensional model a vascular cost, VC cdl , for each candidate delivery location (130, a to c) which is related to an accessibility of the candidate delivery location (130, a to c) by a tip (202) of the vascular catheter (200), wherein the evaluating comprises using the vascular cost for each candidate delivery location (130, a to c) and a likelihood that the substance flowing from the candidate delivery location (130, a to c) towards the target will flow through one or more arterial branches converging with the target and into the target when delivered at the candidate delivery location (130, a to c) by the tip of the vascular catheter.

The invention discloses a net ultrafiltration rate intelligent regulation and control device and method for CRRT treatment, and relates to the technical field of medical equipment control, and the device comprises a sensor module, a data processing module and a regulation and control module; the sensor module is used for acquiring CRRT treatment associated data of a preset patient; the data processing module is used for predicting a blood volume tolerance curve of a preset patient by utilizing an artificial intelligence technology according to historical CRRT treatment data and CRRT treatment associated data of the preset patient, and generating a net ultrafiltration rate time sequence scheme according to the predicted blood volume tolerance curve and a preset treatment target of the preset patient; and the regulation and control module is used for automatically regulating the rotating speed of a blood pump and the rotating speed of a displacement liquid pump which are used for performing CRRT treatment on the preset patient according to the net ultrafiltration rate time sequence scheme, and regulating the dehydration rate of the preset patient. According to the invention, a more accurate intelligent regulation and control mode can be provided for CRRT treatment.

The invention is applicable to the technical field of molecular biology, and provides a macrophage related gene KCNA3 and application thereof. The invention discloses a macrophage related gene KCNA3 for the first time, and the gene is identified as a macrophage related differential expression gene of a patient with type 2 diabetes mellitus with carotid atherosclerosis, and shows high expression in the patient with type 2 diabetes mellitus with carotid atherosclerosis. Through analysis of a public database transcriptome chip and high-throughput sequencing data and further verification of CIBERSORTX and WGCNA algorithms, close association between the KCNA3 gene and the macrophages is confirmed. Based on differentiated expression of the KCNA3 gene and correlation of the KCNA3 gene and macrophages, the gene can be used as a potential treatment target for further treating patients with the diabetes mellitus with the carotid atherosclerotic plaque, so that a new mechanism participating in disease progression of the diabetes mellitus with the carotid atherosclerotic plaque is disclosed.

The invention relates to the field of biological medicine, in particular to application of a reagent for measuring or regulating the expression level of HIF-1alpha in preparation of a kit for diagnosing or gout, the kit containing the reagent and a gout prediction device. The HIF-1alpha is applied as a gout diagnosis target and a treatment target for the first time, the polarization degree of Th17 cells in an inflammatory microenvironment of a gout patient can be specifically reflected, early dynamic monitoring of gout related inflammatory activities is achieved, polarization of Th17 cells and expression of related proinflammatory factors are inhibited in a targeted mode, and a new strategy is provided for prediction, diagnosis and treatment of gout.

The invention discloses a method for treating chicken chronic respiratory diseases by using MG-sEV-miRNA-200, and belongs to the technical field of exosomes, and the method comprises the following steps: step 1, constructing an MG infected cell model, and carrying out fluorescence quantitative analysis on gga-miR-200a-3p in cells / exosomes in different time periods of infection; step 2, carrying out overexpression on the miR-200 in the ACE II cells, and extracting an exosome (MG-sEV-miRNA-200) rich in the miR-200; step 3, constructing a cell model for exosome treatment, and carrying out RNA-seq sequencing to identify an exosome treatment target and a pathway rich in gga-miR-200a-3p; step 4, constructing a chick embryo model infected by MG, and injecting MG-sEV-miRNA-200 to intervene in respiratory diseases caused by MG; 5, evaluating the curative effect; mG-sEV is taken as a medium, miRNA can be protected from being influenced by RNA enzyme activity, the gga-miR-200a-3p-rich MG-sEV has the advantages of low immunogenicity, low cytotoxicity, relatively high stability, relatively high biocompatibility and the like, and the MG-sEV rich in gga-miR-200a-3p can be used for remarkably relieving lung inflammation injury caused by MG infection and reducing the bacterium carrying amount of MG in lung tissues; the method has a wide application prospect in the treatment of chicken chronic respiratory diseases.

The invention discloses application of HOXD1 in diagnosis, prognosis and treatment of liver cancer, and particularly relates to application of a reagent for detecting expression of a biomarker HOXD1 in preparation of a product for diagnosing a liver cancer object. The invention discloses application of a reagent for detecting expression of a biomarker HOXD1 in preparation of a product for prognosis of a liver cancer object. The invention discloses an application of HOXD1 as a target in screening medicines for treating liver cancer. The HOXD1 expression inhibitor is applied to preparation of a medicine for treating liver cancer. Differential expression of the HOXD1 in hepatocellular carcinoma tissues and normal hepatocellular carcinoma tissues is clear through research, high expression of the HOXD1 is closely related to the survival reduction period of clinical hepatocellular carcinoma patients, specific knock-down of the HOXD1 can obviously reduce the proliferation capacity of the hepatocellular carcinoma, and a new diagnosis / prognosis marker and a treatment target are provided for early discovery, early treatment and prognosis of the hepatocellular carcinoma. And a new treatment strategy and direction are provided.

The invention belongs to the field of biological medicine, and discloses a blood marker for identifying epilepsy convulsion and application thereof. The inventor finds that the LRG1 is obviously increased during epileptic convulsion, which indicates that the increase of the blood LRG1 is a blood marker during the acute attack stage of epileptic convulsion. The invention proposes and verifies that the LRG1 is the peripheral blood marker in the acute attack stage of epilepsy convulsion for the first time, and can be used as a clinical auxiliary diagnosis and treatment target.

The invention relates to the technical field of biological medicine, in particular to a lymphatic metastatic breast cancer treatment target and application thereof. The exosome piR-hsa-28212 disclosed by the invention can synergistically enhance VEGFC / VEGFR3 signal transduction, so that lymphatic vessel generation in breast cancer is promoted, and the potential of the exosome piR-hsa-28212 serving as a treatment target of lymphatic metastatic breast cancer is indicated. Besides, piR-hsa-28212 in the serum exosome of the breast cancer patient with lymphatic metastasis is obviously up-regulated, so that the piR-hsa-28212 can be used as a serum marker for predicting the lymphatic metastasis of the breast cancer, and has the advantages of noninvasive property, in-vitro stability, acquisition of samples and the like.

The invention discloses application of SHC3 as a diagnosis and prognosis marker and a treatment target of lung metastasis of breast cancer. The research shows that the expression of SHC3 in TNBC lung metastatic cells is remarkably up-regulated, and the up-regulation is closely related to the prognosis of TNBC patients; the increase of SHC3 expression is positively correlated with the migration ability of the TNBC cells, which proves that the SHC3 gene is obviously up-regulated in the TNBC cells of pneumophilic metastasis and can be used as a biomarker of lung metastasis of breast cancer; researches show that silence of SHC3 can significantly weaken the metastasis ability of TNBC and reduce the number of pulmonary metastasis nodules, overexpression of SHC3 can enhance the metastasis activity of TNBC, and SHC3 can be used as a therapeutic target of breast cancer pulmonary metastasis; the invention provides a new marker for prognosis of breast cancer and diagnosis of lung metastasis of breast cancer, and provides a new target and treatment strategy and direction for treatment of lung metastasis of breast cancer.

A system for treatment target tissue comprises an ablation device and an energy delivery unit. The ablation device comprises an elongate tube with an expandable treatment element. The system delivers a thermal dose of energy to treat the target tissue. Methods of treating target tissue are also provided.

The invention discloses application of annular RNACirc3426 as a diagnostic marker and a therapeutic target of colorectal cancer. Experiments show that the Circ3426 is highly expressed in colorectal cancer cells and patient serum, and prove that the Circ3426 has good stability, and an ROC curve shows that the Circ3426 has good capacity of diagnosing colorectal cancer. Meanwhile, it is found that the molecule can promote migration and invasion ability of colorectal cancer cells, nude mouse subcutaneous tumor formation experiments prove that knock-down Circ3426 inhibits growth of tumors, and it is indicated that the molecule can serve as a treatment target of colorectal cancer. The invention provides a new diagnostic marker and a treatment target for colorectal cancer, and provides a new thought and direction for CRC diagnosis and treatment.

The invention belongs to the technical field of biological medicines, and particularly relates to application of NAT10 as a target spot in diagnosis and treatment of acute myelogenous leukemia with high expression of NAT10. The invention discloses that the NAT10 can be used as a diagnosis and treatment target of the acute myelogenous leukemia with high expression of the NAT10 for the first time, and the acute myelogenous leukemia with high expression of the NAT10 can be prevented and / or treated by adopting the NAT10 inhibitor; by detecting the content, the expression quantity and / or the activity of the NAT10, the purposes of diagnosis, monitoring, curative effect evaluation and / or prognosis evaluation of the acute myelogenous leukemia with high expression of the NAT10 can be achieved.

The invention provides an infrared physiotherapy cabin system and method based on animal and environment cooperative regulation and control, and relates to the field of animal physiotherapy and intelligent monitoring control. Comprising an animal state and cabin environment monitoring module, an infrared physiotherapy and cabin environment regulation and control module, an animal health assessment and curative effect assessment module, a personalized treatment and intelligent decision module and a man-machine interaction and safety supervision module. A credibility result is formed through multi-modal data synchronous alignment and data quality evaluation, health state characterization is constructed under credibility gating, a risk level is output, and infrared physiotherapy control parameters and cabin environment regulation and control parameters are generated through cooperative control under the constraint of a stage control boundary and a treatment target and are issued and executed. Continuously adjustable parameters are subjected to online fine adjustment in the physiotherapy process, and rollback and interlocking protection is executed when the risk is increased or the credibility is reduced; after the period is finished, the curative effect is evaluated, data recording and tracing archiving are completed, and collaborative closed-loop infrared physiotherapy regulation and control of the animal state and the in-cabin environment are achieved.

A TMS coil assembly for magnetically stimulating a brain region of a subject, the TMS coil assembly comprising one or more coil assemblies each including adjacently or spaced apart flexible wing-like coil structures configured to adjustably deform along a tilt axis passing between the wing-like coil structures to conform to a curved surface of the subject's head and apply a desired tilt angle between the wing-like coil structures while bringing a substantial loop portion of the wing-like coil structures into direct contact with the curved surface of the head, thereby maximizing the loop portion tangential to the curved surface of the head and minimizing the loop portion non-tangential to the curved surface. A fixation device can be used to maintain the desired tilt angle between the wing-like coil structures when positioned on the subject's head during a TMS procedure, thereby maximizing the strength of the electric field induced at the head.

The invention relates to the crossing field of computer technology and edge calculation, and discloses a blood purification equipment real-time control method based on edge calculation. According to the method, multi-modal real-time physiological parameters, historical dialysis data and a current treatment target are fused through a local edge calculation unit, an individualized body fluid dynamic response prediction model is constructed, and an ultrafiltration rate instruction is optimized and generated within a millisecond level; the system comprises a multi-mode sensor array, a historical data storage module, a task planning interface, an edge computing unit and an ultrafiltration pump controller. According to the application, the hemodynamic state is accurately maintained, the risk of hypotension is remarkably reduced, and the treatment safety and individualization level are improved.

The invention relates to the technical field of biological medicines, and provides application of NR1D1 in treating sicca syndrome, related medicines and the like. The scheme of the invention discovers and proves that the NR1D1 gene participates in the sicca syndrome pathogenesis process, can significantly influence the function of submaxillary gland cells, and is an effective sicca syndrome immune inflammation regulation diagnosis and treatment target.

The invention discloses a wearable transcutaneous electric field stimulation system, device and equipment, the system comprises a wearing module, an electrode module and a control module, the wearing module is used for being worn on a target object; the control module is used for acquiring first illness state data, first body data and an expected treatment target; formulating a first stimulation scheme according to the data; determining a first control instruction corresponding to the first stimulation scheme; the electrode module is used for working according to the first control instruction, generating a corresponding alternating electric field in the body of the target object and stimulating the target object through the alternating electric field; the control module is also used for acquiring second illness state data and second body data; determining whether a desired treatment target is achieved; and if not, adjusting the first stimulation scheme to obtain a second stimulation scheme. According to the embodiment of the invention, a personalized stimulation scheme can be formulated.

An exemplary microwave ablation system is provided. The system may use a switching antenna for both microwave heating of target tissue and microwave radiometry to monitor the temperature of the heated tissue to ensure that the desired temperatures are delivered to adequately treat the target tissue and achieve therapeutic goals. The system may integrate switching components into the switching antenna, which eliminates error from heating of the reference termination and heating of the electrical cables.

The invention discloses application of a neutralizing antibody of oncostatin M in preparation of a medicine for treating bronchial pulmonary dysplasia. The application proves that the intrauterine inflammation can cause BPD-like lung lesion to the filial generation mouse, and the OSM expression level in the mouse lung tissue one day after the intrauterine inflammation filial generation is grown is obviously higher than that of a control group; the OSM level of the BPD group is higher than that of the non-BPD group in the umbilical blood sample of the premature infant; in-vitro experiments show that the OSM treatment can cause lung epithelial cell injury; by dripping a recombined OSM neutralizing antibody into the nose of a newborn mouse, down-regulation of the OSM level in the lung of the mouse is realized, filial generation lung injury induced by the intrauterine inflammation can be repaired, and the OSM can be used as a treatment target of the BPD caused by the intrauterine inflammation.

In one aspect, the present disclosure provides a method for identifying treatment targets relating to tumors. In another aspect, the present disclosure provides a method for identifying biomarkers and molecular features of normal and cancer cells.